 |
Doug Macron is the editor of GenomeWeb's Gene Silencing News. He covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies. E-mail Doug Macron or follow his GenomeWeb Twitter account at @Genesilencing. |
Regulus Continues to Aim for Two INDs in 2014, Expects miRNA Biomarker Data in Q3
February 21, 2013
Regulus Continues to Aim for Two INDs in 2014, Expects miRNA Biomarker Data in Q3
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Regulus Selects HCV Drug Candidate, Will Develop without Partner GSK
May 16, 2013 / Gene Silencing News - USPTO Gives OK to Santaris Request for Re-Exam of Regulus miR-122 Patent
January 10, 2013 / Gene Silencing News - In 2012, Top microRNA Drug Developers Pull in Nearly $150M in Funding
December 20, 2012 / Gene Silencing News - With Three Years of Cash in the Bank, Regulus Aims for Two INDs by 2014
November 29, 2012 / Gene Silencing News - Mirna Closes $34.5M Series C Round as microRNA Drugs Gain Investor Interest
October 25, 2012 / Gene Silencing News